Sale!

RSPH9 Gene Primary Ciliary Dyskinesia Type 12 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The RSPH9 gene primary ciliary dyskinesia type 12 genetic test is a specialized diagnostic procedure designed to identify mutations in the RSPH9 gene, which are associated with primary ciliary dyskinesia (PCD) type 12. PCD is a rare genetic disorder that impairs the function of cilia, the microscopic, hair-like structures that line the airways, reproductive system, and other parts of the body. This impairment leads to various clinical manifestations, including chronic respiratory tract infections, reduced fertility, and situs inversus in some cases.

The test specifically targets the RSPH9 gene to confirm a diagnosis of PCD type 12, enabling healthcare providers to tailor treatment plans and management strategies to the individual needs of the patient. Early and accurate diagnosis through genetic testing can significantly improve the quality of life for affected individuals by allowing for timely interventions and support.

Administered by DNA Labs UAE, the test is available for a cost of 4400 AED. The facility utilizes advanced genetic sequencing technologies to ensure accurate and reliable results, providing essential information for individuals suspected of having this condition and their families. By opting for this test at DNA Labs UAE, patients can expect professional service and comprehensive support throughout the diagnostic process.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

RSPH9 Gene Primary Ciliary Dyskinesia Type 12 Genetic Test

At DNA Labs UAE, we offer the RSPH9 Gene Primary Ciliary Dyskinesia Type 12 Genetic Test. This test is designed to analyze the RSPH9 gene, which is associated with primary ciliary dyskinesia type 12.

Test Components

  • Price: 4400.0 AED

Sample Condition

We accept blood or extracted DNA samples for this test. Alternatively, you can provide one drop of blood on an FTA card.

Report Delivery

Expect your test results to be delivered within 3 to 4 weeks.

Method

We utilize NGS (Next-Generation Sequencing) technology to perform this genetic test.

Test Type

This test is specifically designed to diagnose and identify genetic abnormalities related to ear, nose, and throat disorders.

Doctor

An ENT doctor will oversee the testing process and interpret the results.

Test Department

This test falls under the genetics department at DNA Labs UAE.

Pre Test Information

Before undergoing the RSPH9 Gene Primary Ciliary Dyskinesia Type 12 Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by the EYA1 Gene Branchiootic Syndrome Type 1 NGS Genetic DNA Test gene EYA16.

Test Details

The RSPH9 gene is associated with primary ciliary dyskinesia type 12, a genetic disorder that affects the structure and function of cilia in the body. Cilia are tiny, hair-like structures found on the surface of cells and play a crucial role in moving mucus and other substances along the respiratory tract, reproductive system, and other organs.

Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by abnormal ciliary function, leading to recurrent respiratory infections, chronic cough, bronchiectasis, and infertility. PCD can also affect other organs such as the ears, sinuses, and heart.

NGS (Next-Generation Sequencing) genetic testing is a high-throughput method used to analyze multiple genes simultaneously. In the context of PCD, NGS can be used to identify mutations or variations in the RSPH9 gene that may be responsible for the disorder. This type of genetic testing can provide valuable information for diagnosis, prognosis, and genetic counseling.

If you suspect that you or someone you know may have primary ciliary dyskinesia type 12, it is recommended to consult with a healthcare professional or genetic counselor who can guide you through the process of genetic testing and provide appropriate support and guidance.

Test Name RSPH9 Gene Primary ciliary dyskinesia type 12 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ear Nose Throat Disorders
Doctor ENT Doctor
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for EYA1 Gene Branchiootic syndrome type 1 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with EYA1 Gene Branchiootic syndrome type 1 NGS Genetic DNA Test gene EYA16
Test Details

The RSPH9 gene is associated with primary ciliary dyskinesia type 12, a genetic disorder that affects the structure and function of cilia in the body. Cilia are tiny, hair-like structures found on the surface of cells and play a crucial role in moving mucus and other substances along the respiratory tract, reproductive system, and other organs.

Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by abnormal ciliary function, leading to recurrent respiratory infections, chronic cough, bronchiectasis, and infertility. PCD can also affect other organs such as the ears, sinuses, and heart.

NGS (Next-Generation Sequencing) genetic testing is a high-throughput method used to analyze multiple genes simultaneously. In the context of PCD, NGS can be used to identify mutations or variations in the RSPH9 gene that may be responsible for the disorder. This type of genetic testing can provide valuable information for diagnosis, prognosis, and genetic counseling.

If you suspect that you or someone you know may have primary ciliary dyskinesia type 12, it is recommended to consult with a healthcare professional or genetic counselor who can guide you through the process of genetic testing and provide appropriate support and guidance.